Taysha Gene Therapies (TSHA) Could Be 49% Below Fair Value After Russell Index Drop

Simply Wall St.07-10

Taysha Gene Therapies (TSHA) was recently removed from several Russell indexes, including the Russell 3000E and Russell Microcap families, a change that can influence trading flows as passive funds ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2650123138?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-07-10 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2650123138","market":"us","top_or_hot":-1,"title":"Taysha Gene Therapies (TSHA) Could Be 49% Below Fair Value After Russell Index Drop","media":"Simply Wall St.","content":"<div>\n<p>Taysha Gene Therapies (TSHA) was recently removed from several Russell indexes, including the Russell 3000E and Russell Microcap families, a change that can influence trading flows as passive funds ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tsha/taysha-gene-therapies/news/taysha-gene-therapies-tsha-could-be-49-below-fair-value-afte\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Taysha Gene Therapies (TSHA) Could Be 49% Below Fair Value After Russell Index Drop</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTaysha Gene Therapies (TSHA) Could Be 49% Below Fair Value After Russell Index Drop\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-10 20:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tsha/taysha-gene-therapies/news/taysha-gene-therapies-tsha-could-be-49-below-fair-value-afte><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Taysha Gene Therapies (TSHA) was recently removed from several Russell indexes, including the Russell 3000E and Russell Microcap families, a change that can influence trading flows as passive funds ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tsha/taysha-gene-therapies/news/taysha-gene-therapies-tsha-could-be-49-below-fair-value-afte\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tsha/taysha-gene-therapies/news/taysha-gene-therapies-tsha-could-be-49-below-fair-value-afte","article_id":"2650123138","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tsha/taysha-gene-therapies/news/taysha-gene-therapies-tsha-could-be-49-below-fair-value-afte","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2650123138","pubTimestamp":1783686689,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Taysha Gene Therapies (TSHA) was recently removed from several Russell indexes, including the Russell 3000E and Russell Microcap families, a change that can influence trading flows as passive funds rebalance.\nSee our latest analysis for Taysha Gene Therapies.\nDespite the index removals, Taysha Gene Therapies’ recent share price performance has been strong, with a 30 day share price return of 22.57% and a 90 day share price return of 46.33%, while the 1 year total shareholder return sits at a...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","TSHA":"Taysha Gene Therapies, Inc."},"translate_title":"罗素指数下跌后，Taysha Gene Therapies (TSHA) 的股价可能比公允价值低 49%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TSHA":1.5},"content_text":"Taysha Gene Therapies (TSHA) was recently removed from several Russell indexes, including the Russell 3000E and Russell Microcap families, a change that can influence trading flows as passive funds rebalance. See our latest analysis for Taysha Gene Therapies. Despite the index removals, Taysha Gene Therapies’ recent share price performance has been strong, with a 30 day share price return of 22.57% and a 90 day share price return of 46.33%, while the 1 year total shareholder return sits at a very large gain. If this kind of move has you looking beyond a single biotech, it could be a good moment to scan the wider healthcare opportunity set using our 40 healthcare AI stocks Taysha Gene Therapies has delivered very strong recent returns despite being dropped from multiple Russell indexes. The key question now is whether the current share price still reflects an attractive entry or whether enthusiasm has already been fully priced in. AdvertisementMost Popular Narrative: 48.9% Undervalued At a last close of $6.57 versus a narrative fair value of $12.85, Taysha Gene Therapies is framed as significantly undervalued in the most followed model.  Progress in the clinical development of TSHA-102, particularly moving towards the pivotal phase of the REVEAL trials with promising safety and efficacy data, could enhance investor confidence and potentially lead to future revenue growth once regulatory approval is achieved. Ongoing constructive discussions with the FDA about the regulatory pathway for TSHA-102, including potential expedited approval mechanisms like the RMAT designation, may accelerate product approval and market entry, thereby impacting future earnings positively.  Read the complete narrative. Curious what assumptions sit behind that near doubling of fair value? The projected ramp in revenue, shifts in profitability, and the punchy future earnings multiple all feed into this narrative. Result: Fair Value of $12.85 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, Taysha Gene Therapies still faces meaningful risks, including the possibility that TSHA-102 trial results or FDA feedback fall short of the assumptions embedded in this upbeat narrative. Find out about the key risks to this Taysha Gene Therapies narrative. Next Steps With Taysha Gene Therapies framed as both promising and risky, it makes sense to move quickly, review the key data yourself, and weigh up the 2 key rewards and 3 important warning signs. Looking for more investment ideas beyond Taysha Gene Therapies? If Taysha Gene Therapies has sharpened your focus, now is the time to widen your watchlist and uncover other stocks that could suit your approach.  Spot potential turnaround stories early by scanning 20 elite penny stocks with strong financials before the crowd catches on. Zero in on quality companies that may trade below their estimated worth using the 44 high quality undervalued stocks. Build a steadier core to your portfolio by checking stocks in the 73 resilient stocks with low risk scores that come with resilience front and center.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Taysha Gene Therapies might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2650123138","isCrawlerRequest":true}